Research To Practice | Oncology Videos Multiple Myeloma | Addressing Current Questions and Controversies in the Management of Multiple Myeloma — What Clinicians Want to Know
Jan 11, 2023
01:58:09
Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics:
- Front-Line Treatment of Multiple Myeloma (MM)
- Introduction (0:00)
- Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49)
- Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05)
- Dr Orlowski presentation (15:45)
- Integration of Novel Therapies into the Management of Relapsed/Refractory MM
- Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19)
- Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50)
- Dr Fonseca presentation (41:57)
- Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM
- Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27)
- Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00)
- Dr Raje presentation (1:01:12)
- Bispecific Antibodies in the Treatment of MM
- Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38)
- Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28)
- Dr Berdeja presentation (1:22:18)
- Other Investigational Novel Agents for MM
- Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23)
- Dr Lonial presentation (1:39:34)